Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
96 results about "Stem cell marker" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Stem cell markers are genes and their protein products used by scientists to isolate and identify stem cells. Stem cells can also be identified by functional assays. Below is a list of genes/protein products that can be used to identify various types of stem cells, or functional assays that do the same. The initial version of the list below was obtained by mining the PubMed database as described in...
Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
InactiveUS20100273160A1Reduce self-renewal capacityReduce spreadHepatocytesMicrobiological testing/measurementPhysiologyOvarian cancer
The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and / or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and / or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and / or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic / stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.
Owner:THE GENERAL HOSPITAL CORP
Method of preparing an undifferentiated cell
InactiveUS20030166272A1Increase the number ofReduce needGenetically modified cellsGenetic material ingredientsCell biologyUndifferentiated cell
Owner:GHAZI JASWINDER DHOOT
Method of preparing an undifferentiated cell
InactiveUS7410773B2Increase the number ofGenetically modified cellsGenetic material ingredientsUndifferentiated cellStem cell marker
Owner:GHAZI JASWINDER DHOOT
Patient-specific stem cell lines derived from human parthenogenetic blastocysts
InactiveUS20080299091A1Increase alkaline phosphatase activityHigh levelBiocideSenses disorderTelomeraseOocyte donor
Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.
Owner:INT STEM CELL CORP
Integrin CD18 is a novel stromal stem cell marker and functions to promote osteogenesis
InactiveUS7732126B2Bioreactor/fermenter combinationsBiological substance pretreatmentsImmunoperoxidase StainingCancer research
Owner:UNITED STATES OF AMERICA +1
Method for obtaining and storing multipotent stem cells
InactiveUS20070258957A1BiocideMammal material medical ingredientsEmbryonic stem cellMultipotent Stem Cell
Owner:BOWERMASTER RUSSELL +1
Markers of Acute Myeloid Leukemia Stem Cells
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells
InactiveUS20100093089A1Raise the ratioUnknown materialsSkeletal/connective tissue cellsSurface markerMammal
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Establishment method and application of clinical-grade neural stem cell line
InactiveCN103451153ALow tumorigenicityAvoid Tumor RiskNervous disorderMicroorganism based processesClinical gradeNeurulation
The invention belongs to the field of cytobiology and neurobiology, and provides an establishment method and application of a clinical-grade neural stem cell line. The method under GMP (Good Manufacturing Practice) control comprises two steps, namely, primary culturing of neural stem cells, and subculturing of neural stem cells. The identification result shows that the neural stem cell line established by the method can express a plurality of stem cell markers, can be differentiated into nerve cells, astrocyte and oligodendrocyte, has high stability, and is suitable for long-term culturing; a large amount of sufficient clinical-grade neural stem cells can be obtained by the method. The method can be used for establishing the neural stem cell line based on a plurality of neural stem cells and even single neural stem cell, and thus the error in study can be reduced as far as possible. By adopting the neural stem cell line established by the method and the cells obtained by differentiating the neural stem cell line, the problems of the safety and effectiveness risk in cell therapy of nervous system disease can be solved effectively, and safe and effective treatment on such diseases becomes possible.
Owner:栾佐
Isolation and use of melanoma cancer stem cells
ActiveUS9151760B2Peptide/protein ingredientsMicrobiological testing/measurementPrimary tumorFunctional assay
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods
Owner:VAN ANDEL RES INST
Mammary stem cell marker
ActiveUS20070280948A1High expressionGenetic material ingredientsMicrobiological testing/measurementSurface markerLow-density lipoprotein
It is disclosed here that low density lipoprotein receptor-related protein 5 (LRP5) is a cell surface marker for somatic mammary stem cells and mammary tumor stem cells. The disclosure here provides new tools for enriching somatic mammary stem cells and mammary tumor stem cells. Methods of screening for agents that modulate LRP5 activity, of treating mammary tumor or breast cancer, of monitoring somatic mammary stem cells and mammary tumor stem cells in vivo are also provided, and of assessing prognosis of human breast cancer.
Owner:VAN ANDEL RES INST +1
Establishment and application of hepatocellular carcinoma cell line HCC-LY10
InactiveCN102690784AStable passageGood tumorigenicityTumor/cancer cellsVeterinary instrumentsLiver cancerPreclinical phase
The invention provides establishment and application of a hepatocellular carcinoma cell line HCC-LY10. Specifically, the hepatocellular carcinoma cell line HCC-LY10 provided in the invention has stable traits, can be subcultured stably and repeatedly, and is applicable to established animal models of hepatocellular carcinoma, thus being an ideal cell line for the basic and preclinical phase application study of hepatocellular carcinoma. In addition, the hepatocellular carcinoma cell line HCC-LY10 partially expresses hepatocellular carcinoma stem cell marker EpCAM. The invention also provides application of the cell line in establishing model animals, screening drugs, and other aspects.
Owner:SHANGHAI INST OF ONCOLOGY
Unique properties of a stem cells
InactiveUS20050074874A1Rejuvenate aged tissueEasy to detectMicrobiological testing/measurementArtificial cell constructsMammalian tissueMammal
The present invention is directed to unique properties of stem cells, including methods to identify stem cell markers by identifying molecules associated specifically with chromosomes in stem cells. More particularly, we have discovered that somatic stem cells repeatedly inherit an entire complement of chromosomes that contain the same parental template DNA strands from one generation to the next. The present invention also provides methods related to diagnosis, prognosis, and treatments for cancer and aging in mammalian tissus, including human.
Owner:MASSACHUSETTS INST OF TECH
Avian induced pluripotent stem cells and their use
InactiveUS20140363467A1Fast recoveryIncrease the number of cellsSsRNA viruses negative-senseGenetically modified cellsGerm layerReprogramming
The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting / transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected / transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.
Owner:UNIV OF GEORGIA RES FOUND INC
Integrin CD18 is a Novel Stromal Stem Cell Marker and Functions to Promote Osteogenesis
InactiveUS20070248998A1Easy to detectBioreactor/fermenter combinationsBiological substance pretreatmentsImmunoperoxidase StainingCancer research
The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the HMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.
Owner:US DEPT OF HEALTH & HUMAN SERVICES +1
Medium composition for rejuvenating stem cells
Owner:RNL BIO
Cancer stem cell markers and uses thereof
InactiveCN102753199AImmunoglobulins against blood group antigensBiological material analysisAntigenCarbohydrate antigen
Owner:GLYCOTOPE GMBH
Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain
InactiveUS20110002846A1Microbiological testing/measurementRadioactive preparation carriersAbnormal tissue growthProgenitor
The present invention is directed to methods of treating a primary brain tumor and preventing the migratory spread of a primary brain tumor in a subject. These methods involve utilizing the CD24 surface protein selectively expressed on tumor progenitor cells as a therapeutic target as well as a means for directing oncolytic therapeutics directly to the tumor site. The present invention further relates to methods of diagnosing the presence of a brain tumor and monitoring the status of the brain tumor in a subject based on CD24 expression in tumor progenitor cells.
Owner:UNIVERSITY OF ROCHESTER
Method for inducing liver cell cells to be transformed into liver cancer stem cells
ActiveCN106676074ASimple and fast operationCause physical and chemical stressCell culture supports/coatingTumor/cancer cellsCelluloseMicroscopic observation
The invention discloses a method for inducing liver cell cells to be transformed into liver cancer stem cells. The method comprises the following steps: adding human liver cancer cells with a single cell state into a culture medium, so as to prepare a cell suspension solution; dropwise adding the cell suspension solution into a porous cellulose bracket; after enabling the cell suspension solution to permeate into the porous cellulose bracket, putting the porous cellulose bracket into a cell culture box and culturing and adhering; then adding the culture medium into the cell culture box and culturing for a plurality of days to obtain three-dimensional cultured cells; detecting changes of expression conditions of liver cancer stem cell marker molecules EpCAM (Epithelial Cellular Adhesion Molecule), OCT4, CD44 and CD133 in the three-dimensional cultured cells through utilizing Western Blot, quantitative PCR (Polymerase Chain Reaction), flow cytometry and IHC (Immunohistochemistry) and (or) a microscope is used for observing; the transformed liver cancer stem cells are detected. The invention further discloses the liver cancer stem cells and application of the liver cancer stem cells. The liver cancer stem cells disclosed by the invention have good drug resistance.
Owner:NANJING DRUM TOWER HOSPITAL
Joint detection kit for multiple markers on CTCs (circulating tumor cells) and application of kit
InactiveCN107586839AAvoid interferenceUse less bloodMicrobiological testing/measurementLymphatic SpreadHepatocellular carcinoma
The invention provides a joint detection kit for multiple stem cell markers on surfaces of CTCs (circulating tumor cells) and an application of the kit. The joint detection kit for multiple stem cellmarkers on surfaces of CTCs comprises 1) a peripheral blood CTC enrichment reagent; 2) an RNA extraction reagent; 3) an RNA reverse transcription reagent; 4) a fluorescence labeled Taqman probe and aspecific primer; 5) a qPCR reaction system reagent and a hepatocellular carcinoma prediction formula. The kit can be used for biopsy of minimally invasive fluids of tumor patients, early diagnosis andearly warning of tumor metastasis and relapse are realized, the anti-tumor therapy effect and the tumor progression condition are monitored, molecular subtyping based on CTCs and screening of specific sensitive drugs for the CTCs are realized, so that knowledge about tumor metastasis, relapse and drug resistance related mechanisms is improved, individualized medical treatment of tumor patients isguided, the overall survival of the tumor patients is significantly improved, and the kit has great clinical significance.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Isolation and Use of Melanoma Cancer Stem Cells
ActiveUS20120225073A1Delay is slowSufficient amountPeptide/protein ingredientsMicrobiological testing/measurementPrimary tumorFunctional assay
A set of markers for melanoma cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression CD271.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Establishment and application of hepatocellular carcinoma cell line HCC-LY5
InactiveCN102690785AStable passageGood tumorigenicityTumor/cancer cellsVeterinary instrumentsLiver cancerCancer research
The invention provides establishment and application of a hepatocellular carcinoma cell line HCC-LY5. Specifically, the hepatocellular carcinoma cell line HCC-LY5 provided in the invention has stable traits, can be subcultured stably and repeatedly, and is applicable to established animal models of hepatocellular carcinoma, thus being an ideal cell line for the basic and preclinical phase application study of hepatocellular carcinoma. In addition, a very small part of the hepatocellular carcinoma cell line HCC-LY5 expresses hepatocellular carcinoma stem cell marker CD133. The invention also provides application of the cell line in establishing model animals, screening drugs, and other aspects.
Owner:SHANGHAI INST OF ONCOLOGY
Purposes of icaritin in preparing medicaments for inhibiting liver cancer stem cells
InactiveCN105106196AOrganic active ingredientsAntineoplastic agentsMolecular Targeted TherapiesOncology
Owner:BEIJING SHENOGEN PHARMA GRP
Systems and methods employing human stem cell markers for detection, diagnosis and treatment of circulating tumor cells
Owner:CUREMETA DIAGNOSTICS LLC
Markers of acute myeloid leukemia stem cells
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Development of universal cancer drugs and vaccines
ActiveUS9394538B2Reduce the number of copiesStrong specificitySugar derivativesMicrobiological testing/measurementLymphatic SpreadEmbryo
Owner:LIN SHI LUNG +1
Stem cell spheroid induction culture solution and stem cell spheroid culture method
The invention discloses a stem cell spheroid induction culture solution and a stem cell spheroid culture method and belongs to cell culture solutions. The method comprises the steps of enabling cells cultured in an original culture solution to grow to reach 90% in fusion degree, using a mixed culture solution to culture the cells, performing primary anoxia culture in a carbon dioxide culture box until 90% of the cells die; enabling remaining adherent cells to be subjected to phosphate buffered saline (PBS) washing and be added into the original culture solution to continuously being cultured; after the cell density reaches 90%, replacing the original culture solution with the mixed culture solution again, performing secondary anoxia culture, and collecting suspended stem cell spheroids. Besides, the cells are induced in an in vitro environment to continuously generate plenty of stem cell spheroids, and the stem cell spheroids can express specific stem cell markers such as CD44, CD133, OCT3 / 4, Nanog, SOX-2 and ABCG2 which are normal or tumor stem cell markers.
Owner:TIANJIN PEOPLE HOSPITAL
Identification and isolation of neural stem cells and neurosphere initiating cells
The disclosure reports on the identification and isolation of adult mouse lateral ventricle subventricular zone (SVZ) neurosphere initiating cells (NICs) by flow cytometry on the basis of GlastmidEGFRhighPlexinB2highCD24− / lowO4 / PSA-NCAM− / lowTer-119 / CD45− markers (GEPCOT cells). These cells are highly mitotic and short-lived in vivo based on fate-mapping with Ascl1CreERT2 and Dlx1CreERT2. In contrast, pre-GEPCOT cells were quiescent, expressed higher Glast, and lower EGFR and PlexinB2. Pre-GEP-COT cells could not form neurospheres but expressed the stem cell markers Glast-CreERT, GFAP-CreERT2, Sox2CreERT2, and Gli1C-reERT2 and were long-lived in vivo. While GEPCOT NICs were ablated by temozolomide, pre-GEPCOT cells survived and repopulated the SVZ. Conditional deletion of the Bmi-1 polycomb protein depleted pre-GEPCOT and GEPCOT cells, though pre-GEPCOT cells were more dependent upon Bmi-1 for p16Ink4a repression. These data distinguish quiescent NSCs from NICs and make it possible to study their properties in vivo.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Isolated culture method of hair follicle stem cells of Yangtze River delta white goat
InactiveCN109355255AOptimize the extraction processAvoid timeCell dissociation methodsDead animal preservationPhysiologyStem cell line
The invention provides an isolated culture method of hair follicle stem cells of Yangtze River delta white goat. By adoption of the method, an isolated cell line has a good growth and division state,and relatively pure hair follicle stem cells can be obtained and are of a typical paving stone shape; primary cells grow fast, so that aggregated growth of cells can be observed on the third day, morecell aggregates in aggregated growing can be observed on the fourth day, the cells can overgrow 60 to 70 percent of a culture dish on the fifth day, and the positive rate of hair follicle stem cell markers is up to 90 percent or above. Results of cell chromosome analysis, hair follicle stem cell marker detection, cell activity detection and the like show that a built hair follicle stem cell lineof the Yangtze River delta white goat is high in activity, and the hair follicle stem cell markers are high in positive rate; and a good practical model can be provided for researching gene expressionand passageway regulation of skin cells and growth and a mechanisms of skin appendages, in particular for researching a mutual action mechanism among main cells of the skin.
Owner:YANGZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap